Published in Health Business Week, January 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Shire.
Report 1: The European Medicines Agency announced a license variation for Replagal (agalsidase alfa) to include children with Fabry disease from 7 years of age.
The decision to grant the license variation was based on new safety and exploratory efficacy data, which demonstrated that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.